Oligomerix wins $1.7M grant to support research on Alzheimer's drug candidates

09/13/2013 | Pharmaceutical Business Review Online

The NIH's National Institute on Aging awarded Oligomerix a two-year, $1.7 million grant to support its research on small molecule drugs designed to prevent tau oligomer formation, which is believed to play a key role in Alzheimer's disease progression. "This program will allow us to evaluate our lead candidates in animal models of AD and related tauopathies with the goal of selecting candidates for IND enabling studies, a prelude to initial clinical evaluation," Oligomerix President and CEO James Moe said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN